Rainbow Coral Corp. (OTCBB: RBCC) leadership is in San Francisco this week to scout exciting new biotech partnership opportunities at Biotech Showcase ™ 2013.
Biotech Showcase is focused on providing private and public biotechnology companies the opportunity to meet with, and present ideas to, investors and executives from around the world. The major industry event draws the attention of the largest players and investors in biotechnology with investors.
This year, the showcase is expected to attract upwards of 1,500 attendees.
“Biotech Showcase 2013 is a crucial opportunity for our company to network with brilliant young entrepreneurs and emerging businesses with the potential to grow our base of assets and increase our value to shareholders,” said RBCC CEO Patrick Brown. “We’ll be specifically targeting new projects that exhibit short paths to marketability in order to grow our business as quickly as possible.”
The Company’s biotech subsidiary, Rainbow Biosciences, is close to finalizing a joint venture with Amarantus to develop and market new therapies and treatments for both neurological diseases including Parkinson’s and physical traumas such as brain injury.
The company hopes to bolster its portfolio of projects for commercialization at this week’s showcase.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott Laboratories (NYSE: ABT).
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at www.rainbowbiosciences.com. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.